MIRAPEX.com: MIRAPEX as initial monotherapy

Initial monotherapy with MIRAPEX offers effective control of early PD^1,4

When used as initial monotherapy, MIRAPEX provides significant improvements in UPDRS ADL* scores, demonstrating enhanced patient functioning in as few as 3 weeks⁸ Learn more
Initiating monotherapy with MIRAPEX reduces the risk of major motor complications¹⁺ Learn more
Initiating therapy with MIRAPEX helps facilitate a levodopa-saving strategy to reduce the risk of motor complications^1,9 Learn more

Learn how MIRAPEX improves functioning when used as combination therapy

*UPDRS=Unified Parkinson’s Disease Rating Scale; ADL=activities of daily living.
+Major motor complications=wearing off, dyskinesia or "on-off" functions.

Important information about MIRAPEX:

Mirapex® (pramipexole dihydrochloride) tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur.
The most commonly reported adverse events in early and late disease in clinical trials were dizziness, dyskinesia, extrapyramidal syndrome, hallucinations, headache, insomnia, somnolence, and nausea.

Patients and caregivers should be informed that impulse control disorders/compulsive behaviors may occur while taking medicines, including pramipexole, to treat Parkinson's disease.

Please see full Prescribing Information.

This information is intended for US residents only.

Initial monotherapy with MIRAPEX offers effective control of early PD1,4

Initial monotherapy with MIRAPEX offers effective control of early PD^1,4